Amneal Pharmaceuticals Inc Class A (AMRX)

Currency in USD
8.540
+0.330(+4.02%)
Closed·
After Hours
8.400-0.140(-1.64%)
·
AMRX Scorecard
Full Analysis
High shareholder yield
AMRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.2108.580
52 wk Range
6.6859.475
Key Statistics
Prev. Close
8.21
Open
8.21
Day's Range
8.21-8.58
52 wk Range
6.685-9.475
Volume
2.39M
Average Volume (3m)
1.6M
1-Year Change
11.63%
Book Value / Share
-0.36
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AMRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.000
Upside
+40.52%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Amneal Pharmaceuticals Inc Class A Company Profile

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson’s disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson’s disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Employees
8300

Amneal Pharmaceuticals Inc Class A SWOT Analysis


Generic Revival
Explore Amneal's robust growth in generics, particularly injectables, driving a 17% increase in Q3 2024 and positioning the company for sustained expansion
Strategic Diversification
Delve into Amneal's multi-pronged growth strategy, encompassing generics, biosimilars, and specialty pharmaceuticals, with a focus on CREXONT's promising launch
Market Dynamics
Analyst targets range from $9 to $12 per share, reflecting optimism about Amneal's potential in the competitive pharmaceutical landscape
Future Challenges
Learn how Amneal plans to navigate the loss of Rytary exclusivity in 2025 and capitalize on biosimilar opportunities amidst regulatory uncertainties
Read full SWOT analysis

Amneal Pharmaceuticals Inc Class A Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $0.25 beat forecast by 47.06%, revenue of $725M missed slightly; stock rose 4.15% pre-market to $8.29
  • Revenue up 3% YoY, adjusted EBITDA grew 13% to $184M; company raised full-year 2025 guidance, projecting $3.0-3.1B revenue
  • New product launches and strategic partnerships expected to drive growth; company aims to become 'America's #1 affordable medicines company'
  • Analysts maintain strong buy consensus with $11-12 price targets; InvestingPro data shows 36.5% gross profit margin, 11% 5-year revenue CAGR
  • Potential risks include supply chain disruptions, market saturation, macroeconomic pressures, and regulatory challenges in international markets
Last Updated: 05/08/2025, 17:14
Read Full Transcript

Compare AMRX to Peers and Sector

Metrics to compare
AMRX
Peers
Sector
Relationship
P/E Ratio
794.7x12.9x−0.5x
PEG Ratio
7.820.010.00
Price/Book
−23.9x2.0x2.6x
Price / LTM Sales
0.9x1.6x3.3x
Upside (Analyst Target)
40.5%17.6%43.4%
Fair Value Upside
Unlock24.0%7.1%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.000
(+40.52% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
0.25 / 0.17
Revenue / Forecast
725.00M / 748.18M
EPS Revisions
Last 90 days

AMRX Income Statement

People Also Watch

247.45
AVAV
-4.68%
37.72
EXEL
+0.88%
57.20
LNTH
+4.27%
125.01
NBIX
-0.47%
110.81
SKYW
-0.87%

FAQ

What Stock Exchange Does Amneal Pharma A Trade On?

Amneal Pharma A is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Amneal Pharma A?

The stock symbol for Amneal Pharma A is "AMRX."

What Is the Amneal Pharma A Market Cap?

As of today, Amneal Pharma A market cap is 2.68B.

What Is Amneal Pharma A's Earnings Per Share (TTM)?

The Amneal Pharma A EPS (TTM) is 0.01.

When Is the Next Amneal Pharma A Earnings Date?

Amneal Pharma A will release its next earnings report on 06 Nov 2025.

From a Technical Analysis Perspective, Is AMRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Amneal Pharma A Stock Split?

Amneal Pharma A has split 0 times.

How Many Employees Does Amneal Pharma A Have?

Amneal Pharma A has 8300 employees.

What is the current trading status of Amneal Pharma A (AMRX)?

As of 10 Aug 2025, Amneal Pharma A (AMRX) is trading at a price of 8.54, with a previous close of 8.21. The stock has fluctuated within a day range of 8.21 to 8.58, while its 52-week range spans from 6.69 to 9.48.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.